Skip to main content
Fig. 5 | Journal of Neuroinflammation

Fig. 5

From: GPR110 (ADGRF1) mediates anti-inflammatory effects of N-docosahexaenoylethanolamine

Fig. 5

Proposed model for synaptamide/GPR110-mediated suppression of LPS-induced neuroinflammation. LPS induces activation of peripheral immune cells such as neutrophils and macrophages, which increases the level of pro-inflammatory mediators. Under systemic inflammatory conditions, inflammatory molecules produced by peripheral immune cells traverse the blood-brain barrier and activate microglia causing neuroinflammation. Pharmacologically administered synaptamide acts on central and peripheral targets where GPR110 is expressed or induced after LPS challenge to ameliorate neuroinflammation through cAMP-dependent immune regulatory mechanisms. Synaptamide endogenously produced from DHA in the brain or peripheral tissues can also be protective

Back to article page